Potential Market, page-18

At least an outcome of designing the trial to meet FDA's request was a very solid result in the liver, I anticipate the oncology community will respond well to this finding and the p value will be well received. SirSpheres clearly have efficacy in first line in their target organ. A recommendation in NCCN or ESMO guidelines would be nice, but may have to wait for OS data to get this. Expecting dose sales for earlier line should still kick upwards in the meantime on the back of SIRFLOX results, if clinicians wish to control the liver disease they now have level 1 evidence that SirSpheres can help achieve this.